SEC Form S-8 filed by Akebia Therapeutics Inc.

$AKBA
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $AKBA alert in real time by email
S-8 1 d775128ds8.htm S-8 S-8

As filed with the Securities and Exchange Commission on January 30, 2025

Registration No. 333-   

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

AKEBIA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   20-8756903

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

245 First Street, Cambridge, MA   02142
(Address of Principal Executive Offices)   (Zip Code)

Inducement Stock Option Awards (January 2024 – December 2024)

(Full title of the plan)

Carolyn M. Rucci

Senior Vice President, Legal and General Counsel and Secretary

Akebia Therapeutics, Inc.

245 First Street

Cambridge, MA 02142

(Name and address of agent for service)

(617) 871-2098

(Telephone number, including area code, of agent for service)

Please send copies of all communications to:

Caroline Dotolo

Wilmer Cutler Pickering Hale and Dorr LLP

60 State Street

Boston, MA 02109

617-526-6000

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer      Accelerated filer  
Non-accelerated filer      Smaller reporting company  
     Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

 

 


PART I

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

Item 1. Plan Information.

The information required by Item 1 is omitted from this Registration Statement and included in documents sent or given to participants in the plan covered by this Registration Statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”).

Item 2. Registrant Information and Employee Plan Annual Information.

The written statement required by Item 2 is omitted from this Registration Statement and included in documents sent or given to participants in the plan covered by this Registration Statement pursuant to Rule 428(b)(1) of the Securities Act.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The Registrant is subject to the informational and reporting requirements of Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the “Commission”). The following documents, which are on file with the Commission, are incorporated in this Registration Statement by reference:

(a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December  31, 2023, as filed with the Commission on March 14, 2024, including the information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K from the Registrant’s definitive proxy statement for the 2024 Annual Meeting of Stockholders, filed with the Commission on April  25, 2024;

(b) The Registrant’s Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2024, June 30, 2024 and September  30, 2024, as filed with the Commission on May  9, 2024, August  8, 2024 and November 7, 2024, respectively;

(c) The Registrant’s Current Reports on Form 8-K as filed with the Commission on January  8, 2024, January  30, 2024, February  13, 2024, March  15, 2024, March  28, 2024, April  16, 2024, April  23, 2024, June  10, 2024, June  24, 2024, July  11, 2024, October  16, 2024, and January 13, 2025. Any report or portion thereof “furnished” on Form 8-K shall not be incorporated by reference; and

(d) The description of the Registrant’s securities contained in the Registrant’s Registration Statement on Form 8-A, as filed with the Commission on March  12, 2014 under the Exchange Act, as the description therein has been updated and superseded by the description of the Registrant’s capital stock contained in Exhibit 4.6 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the Commission on February 25, 2021, including any amendments or reports filed for the purpose of updating such description.

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.


Item 4. Description of Securities.

Not applicable.

Item 5. Interests of Named Experts and Counsel.

Not applicable.

Item 6. Indemnification of Directors and Officers

The Registrant’s Ninth Amended and Restated Certificate of Incorporation contains provisions that eliminate, to the maximum extent permitted by the General Corporation Law of the State of Delaware (the “DGCL”), the personal liability of directors for monetary damages for breach of their fiduciary duties as a director. The Registrant’s Ninth Amended and Restated Certificate of Incorporation and Second Amended and Restated Bylaws (“Amended and Restated Bylaws”) provide that the Registrant shall indemnify its directors and executive officers and may indemnify its employees and other agents to the fullest extent permitted by the DGCL.

Section 145 of the DGCL empowers a Delaware corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the rights of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise. The indemnity may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person. The statute provides that it is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise.

Section 102(b)(7) of the DGCL permits a corporation to provide in its charter that a director or officer of the corporation will not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, except for liability (1) for any breach of the director’s or officer’s duty of loyalty to the corporation or its stockholders, (2) for a director’s or officer’s acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3) for a director, for payments of unlawful dividends or unlawful stock purchases or redemptions, (4) for any transaction from which the director or officer derived an improper personal benefit or (5) for an officer, in any action by or in the right of the corporation.

The Registrant has entered into indemnification agreements with each of its directors and officers, in addition to the indemnification provided for in the Registrant’s Ninth Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws.

The Registrant maintains insurance on behalf of any person who is or was a director or officer of the Registrant against any loss arising from any claim asserted against him or her and incurred by him or her in any such capacity, subject to certain exclusions.

Item 7. Exemption from Registration Claimed.

Not applicable.


Item 8. Exhibits.

 

Exhibit
No.

  

Description

 4.1    Ninth Amended and Restated Certificate of Incorporation (previously filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on March 28, 2014 (File No. 001-36352) and incorporated herein by reference).
 4.2    Certificate of Amendment of Ninth Amended and Restated Certificate of Incorporation of Akebia Therapeutics, Inc. (previously filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on June 9, 2020 (File No. 001-36352) and incorporated herein by reference).
 4.3    Second Amended and Restated Bylaws (previously filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on April 28, 2023 (File No. 001-36352) and incorporated herein by reference).
 5.1    Opinion of Wilmer Cutler Pickering Hale and Dorr LLP (filed herewith).
23.1    Consent of Ernst & Young LLP (filed herewith).
23.2    Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in the opinion filed as Exhibit 5.1).
24.1    Power of attorney (included on the signature page of this Registration Statement under the caption “Power of Attorney and Signatures”).
99.1    Form of Officer Inducement Award Stock Option Agreement under 2023 Stock Incentive Plan (Reflecting Clawback Policy) (previously filed as Exhibit 10.47 to the Company’s Annual Report on Form 10-K (001-36352) filed on March 14, 2024 and incorporated herein by reference).
99.2    Form of Non-Officer Inducement Award Stock Option Agreement under 2023 Stock Incentive Plan (filed herewith).
107    Filing Fee Table (filed herewith).


Item 9. Undertakings.

(a) The undersigned Registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

 

  (i)

To include any prospectus required by Section 10(a)(3) of the Securities Act;

 

  (ii)

To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement; and

 

  (iii)

To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above shall not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 30th day of January, 2025.

 

AKEBIA THERAPEUTICS, INC.
By:   /s/ John P. Butler
  Name: John P. Butler
  Title: President and Chief Executive Officer


POWER OF ATTORNEY AND SIGNATURES

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John P. Butler and Erik J. Ostrowski, and each of them, either of whom may act without the joinder of the other as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

  

Capacity

 

Date

/s/ Adrian Adams

Adrian Adams

   Chairperson and Director   January 30, 2025

/s/ John P. Butler

John P. Butler

  

Director, President and Chief Executive Officer

(Principal Executive Officer)

  January 30, 2025

/s/ Erik J. Ostrowski

Erik J. Ostrowski

  

Senior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer

(Principal Financial Officer)

  January 30, 2025

/s/ Richard C. Malabre

Richard C. Malabre

  

Senior Vice President, Chief Accounting Officer

(Principal Accounting Officer)

  January 30, 2025

/s/ Ron Frieson

Ron Frieson

   Director   January 30, 2025

/s/ Steven C. Gilman

Steven C. Gilman

   Director   January 30, 2025


Signature

  

Capacity

 

Date

/s/ Michael Rogers

Michael Rogers

   Director   January 30, 2025

/s/ Cynthia Smith

Cynthia Smith

   Director   January 30, 2025

/s/ Myles Wolf

Myles Wolf

   Director   January 30, 2025

/s/ LeAnne M. Zumwalt

LeAnne M. Zumwalt

   Director   January 30, 2025
Get the next $AKBA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AKBA

DatePrice TargetRatingAnalyst
11/29/2023$4.00Buy
BTIG Research
8/28/2023$3.75Neutral → Buy
H.C. Wainwright
5/31/2023$2.00 → $4.00Neutral → Overweight
Piper Sandler
3/31/2022$10.00 → $2.00Buy → Neutral
H.C. Wainwright
3/31/2022Buy → Hold
Needham
3/31/2022$6.00 → $2.00Buy → Neutral
Mizuho
3/31/2022$6.00 → $2.00Overweight → Neutral
Piper Sandler
11/11/2021$6.00 → $10.00Buy
HC Wainwright & Co.
More analyst ratings

$AKBA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

    CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25), which will take place in Boston, MA from April 10-13, 2025. Akebia-supported posters will be displayed at NKF SCM25 during Exhibit Hall hours. Cardiovascular Risk in Patients With DD-CKD Randomized to Vadadustat vs Darbepoetin Alfa With or Without Cardiovascular Disease: Poster: G-284 Vadadustat for Treatment of Anemia in Older vs Younger Patients With Dialysis-Dependent-CKD:

    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

    CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. ("Akebia") (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the pricing of its underwritten public offering (the "Offering") of 25,000,000 shares of its common stock at a public offering price of $2.00 per share. All shares are being offered by Akebia. The gross proceeds to Akebia from the Offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be $50.0 million. In addition, Akebia has granted the underwriters a 30-day option to purchase up to 3,750,000 additional shares of it

    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Akebia Therapeutics Announces Proposed Public Offering of Common Stock

    CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. ("Akebia") (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has commenced an underwritten public offering (the "Offering"). All shares are being offered by Akebia. In addition, Akebia expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the Offering at the public offering price, less underwriting discounts and commissions. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may

    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$AKBA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AKBA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AKBA
SEC Filings

See more

$AKBA
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

    Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$AKBA
Leadership Updates

Live Leadership Updates

See more
  • Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer

    CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer. Mr. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty markets. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeut

    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Akebia Therapeutics Appoints Ron Frieson, Healthcare Operations Leader, to Board of Directors

    CAMBRIDGE, Mass., Nov. 1, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Ron Frieson to its Board of Directors. Frieson currently serves as the Chief Operating Officer of Children's Healthcare of Atlanta (CHOA), a non-profit corporation whose mission focuses on bettering all aspects of children's healthcare. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt

    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$AKBA
Financials

Live finance-specific insights

See more
  • Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

    Strong results to date of Vafseo U.S. launch; expect Vafseo Q1 2025 net product revenues of approximately $10-$11 million Cash resources and cash from operations expected to fund current operating plan for at least two years Akebia to Host Conference Call at 8:00 a.m. ET on March 13, 2025 CAMBRIDGE, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the fourth quarter and full year ended December 31, 2024 and recent business highlights. As previously announced, Vafseo® (vadadustat) shipments to customers began Januar

    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

    CAMBRIDGE, Mass., March 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2024, on Thursday, March 13, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, March 13, 2024, at 8:00 a.m. ET to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.  A live web

    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

    Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for VafseoVafseo granted TDAPA reimbursement and issued a Level II Healthcare Common Procedure Coding System codeAkebia to Host Conference Call at 8:00 a.m. ET on November 7CAMBRIDGE, Mass., Nov. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the third quarter ended September 30, 2024, and recent business highlights.

    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$AKBA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more